Clal Biotechnology (Israel) Today
| CBI Stock | 33.60 0.10 0.30% |
PerformanceVery Weak
| Odds Of DistressAverage
|
Clal Biotechnology is trading at 33.60 as of the 26th of March 2025, a 0.3 percent decrease since the beginning of the trading day. The stock's open price was 33.7. Clal Biotechnology has over 55 % chance of experiencing financial distress in the next 2 years of operation and has generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 26th of December 2024 and ending today, the 26th of March 2025. Click here to learn more.
Clal Biotechnology Industries Ltd. is a private equity and venture capital firm specializing in development stage, pre-clinical incubation, seed, start-up, early venture, emerging growth, mid venture, late venture, PIPEs, and growth capital stages of financing. The company has 156.85 M outstanding shares. More on Clal Biotechnology Industries
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Clal Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Clal Biotechnology's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Clal Biotechnology or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Thematic Ideas | (View all Themes) |
| Business Concentration | IT, Biotech, Computers, Health Care, Biotechnology, Biotechnology, Healthcare, Computing (View all Sectors) |
Clal Biotechnology Industries (CBI) is traded on Tel Aviv Stock Exchange in Israel and employs 21 people. The company currently falls under 'Small-Cap' category with a current market capitalization of 122.65 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Clal Biotechnology's market, we take the total number of its shares issued and multiply it by Clal Biotechnology's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Clal Biotechnology operates under Biotechnology sector and is part of Health Care industry. The entity has 156.85 M outstanding shares.
Clal Biotechnology Industries has accumulated about 94.71 M in cash with (41.33 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.59.
Check Clal Biotechnology Probability Of Bankruptcy
Ownership AllocationClal Biotechnology holds a total of 156.85 Million outstanding shares. Clal Biotechnology Industries shows majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 64.58 percent of Clal Biotechnology outstanding shares that are owned by insiders signifies that they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Clal Ownership Details
Clal Biotechnology Risk Profiles
Although Clal Biotechnology's alpha and beta are two of the key measurements used to evaluate Clal Biotechnology's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 1.54 | |||
| Standard Deviation | 2.07 | |||
| Variance | 4.29 | |||
| Risk Adjusted Performance | (0.04) |
Clal Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Clal Biotechnology without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Risk-Return Analysis Now
Risk-Return AnalysisView associations between returns expected from investment and the risk you assume |
| All Next | Launch Module |
Clal Biotechnology Corporate Management
Elected by the shareholders, the Clal Biotechnology's board of directors comprises two types of representatives: Clal Biotechnology inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Clal. The board's role is to monitor Clal Biotechnology's management team and ensure that shareholders' interests are well served. Clal Biotechnology's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Clal Biotechnology's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Assaf Segal | Acting Officer | Profile | |
| Iris Sadeh | Accountant | Profile | |
| Liat Nissan | Controller | Profile | |
| Shiran Manor | Co Sec | Profile | |
| Etty Kliger | VP MediWound | Profile | |
| Arnon MD | Medical Director | Profile | |
| Pr MD | VP MediWound | Profile |
Other Information on Investing in Clal Stock
Clal Biotechnology financial ratios help investors to determine whether Clal Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Clal with respect to the benefits of owning Clal Biotechnology security.